Wessam Ibrahim
About Wessam Ibrahim
Wessam Ibrahim is the Strategy and Operations Lead for the Gulf and Eastern Mediterranean Cluster at Bristol-Myers Squibb, with over two decades of experience in the pharmaceutical and biopharma sectors.
Current Role at Bristol-Myers Squibb
Wessam Ibrahim currently serves as the Strategy and Operations Lead for the Gulf and Eastern Mediterranean Cluster at Bristol-Myers Squibb in New Jersey, United States. In this role, Wessam oversees strategic initiatives and operational efficiencies across the specified regions. This position has been held since 2018 and involves high-level decision-making and leadership.
Previous Roles at Bristol-Myers Squibb
Before assuming his current position, Wessam Ibrahim held numerous roles at Bristol-Myers Squibb. From 2017 to 2018, he was the Specialty Franchise Lead for the Gulf and Eastern Mediterranean Cluster. Prior to that, he served as the Marketing and Access Lead for Immuno-Oncology and Hematology in the Levant and Egypt Cluster from 2016 to 2017. From 2014 to 2016, Wessam acted as the BMS-Pfizer Alliance Product Manager for Eliquis.
International Experience
Wessam Ibrahim's career is marked by extensive international experience, having worked in multiple countries and regions. He has held positions in Mexico, Switzerland, and the UAE. His roles have included Marketing Manager at Wolf Pharma in Mexico, and various roles at Novartis in Switzerland and the UAE, such as Brand Manager for Multiple Sclerosis and Product Specialist for Oncology and Hematology.
Education and Expertise
Wessam Ibrahim holds a Master of Business Administration (MBA) from Hult International Business School. Additionally, he earned a Bachelor's degree from Alexandria University, studying at the Faculty of Pharmacy. His academic background complements his extensive professional experience in the biopharma industry.
Biopharma Marketing and Access Experience
Wessam Ibrahim has significant experience in the biopharma industry, particularly in marketing and access roles. He has managed oncology and hematology portfolios and contributed to high-profile pharmaceutical alliances, such as the BMS-Pfizer Alliance. His career spans over two decades, including leadership positions in both the Gulf and Eastern Mediterranean regions.